Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 96,500 shares, a growth of 94.6% from the February 13th total of 49,600 shares. Based on an average daily trading volume, of 135,800 shares, the short-interest ratio is presently 0.7 days. Approximately 0.4% of the shares of the stock are sold short.
Abrdn Life Sciences Investors Trading Down 0.3 %
HQL stock traded down $0.04 during trading on Friday, hitting $12.95. The stock had a trading volume of 73,073 shares, compared to its average volume of 97,397. The company’s 50 day moving average price is $13.67 and its two-hundred day moving average price is $14.25. Abrdn Life Sciences Investors has a 1-year low of $12.69 and a 1-year high of $15.90.
Abrdn Life Sciences Investors Cuts Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Friday, February 21st will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 14.52%. The ex-dividend date is Friday, February 21st.
Insider Buying and Selling
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. Absolute Investment Advisers LLC acquired a new position in shares of Abrdn Life Sciences Investors during the 4th quarter valued at about $5,242,000. Sanctuary Advisors LLC increased its stake in shares of Abrdn Life Sciences Investors by 11.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock valued at $183,000 after acquiring an additional 1,355 shares during the last quarter. Penserra Capital Management LLC acquired a new position in shares of Abrdn Life Sciences Investors during the 3rd quarter valued at about $11,702,000. Wolverine Asset Management LLC acquired a new position in shares of Abrdn Life Sciences Investors during the 4th quarter valued at about $1,594,000. Finally, Janney Montgomery Scott LLC increased its stake in shares of Abrdn Life Sciences Investors by 7.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 91,398 shares of the company’s stock valued at $1,199,000 after acquiring an additional 6,200 shares during the last quarter. Institutional investors and hedge funds own 32.21% of the company’s stock.
About Abrdn Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Read More
- Five stocks we like better than Abrdn Life Sciences Investors
- Canada Bond Market Holiday: How to Invest and Trade
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- 10 Best Airline Stocks to Buy
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Invest in Biotech Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.